0.9% Sodium Chloride Injection, USP

Manufacturer
Fresenius Kabi USA, LLC | Fresenius Kabi Deutschland GmbH
Effective date
2021-12-21
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 20:40:00

Label at a glance#

ProductSodium Chloride
Active ingredientSODIUM CHLORIDE
Label structure14 sections

Indications and uses

Intravenous solutions containing sodium chloride are indicated for parenteral replenishment of fluid and sodium chloride as required by the clinical condition of the patient.

Dosage and administration

The dose is dependent upon the age, weight and clinical condition of the patient. Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit (see PRECAUTIONS ).

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

DESCRIPTION

DESCRIPTION SECTION

0.9% Sodium Chloride Injection, USP solution is sterile and nonpyrogenic. It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration.

For 0.9% Sodium Chloride Injection, USP, each 100 mL contains 900 mg sodium chloride in water for injection. Electrolytes per 1,000 mL: sodium 154 mEq; chloride 154 mEq. The osmolarity is 308 mOsmol/L (calc.).

The pH in the 100 mL and smaller containers is 6.0; for the 250 mL and larger containers, the pH is 5.6. The pH range is 4.5 to 7.0 for all containers.

The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only as a single-dose injection. When smaller doses are required the unused portion should be discarded.

The solution is a parenteral fluid and electrolyte replenisher.

Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water.

Water for injection, USP is chemically designated H2O.

The flexible container is fabricated from a specially formulated non-plasticized, film containing polypropylene and thermoplastic elastomers (free flex ® bag). The amount of water that can permeate from the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the flexible container can leach out certain of the container's chemical components in very small amounts within the expiration period. The suitability of the container material has been confirmed by tests in animals according to USP biological tests for plastic containers.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

When administered intravenously, the solution provides a source of water and electrolytes.

Solutions which provide combinations of hypotonic or isotonic concentrations of sodium chloride are suitable for parenteral maintenance or replacement of water and electrolyte requirements.

Isotonic concentrations of sodium chloride are suitable for parenteral replacement of chloride losses that exceed or equal the sodium loss. Hypotonic concentrations of sodium chloride are suited for parenteral maintenance of water requirements when only small quantities of salt are desired. A hypertonic concentration of sodium chloride may be used to repair severe salt depletion syndrome.

Sodium chloride in water dissociates to provide sodium (Na+) and chloride (Cl-) ions. Sodium (Na+) is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Chloride (Cl-) has an integral role in buffering action when oxygen and carbon dioxide exchange occurs in the red blood cells. The distribution and excretion of sodium (Na+) and chloride (Cl-) are largely under the control of the kidney which maintains a balance between intake and output.

Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirements range from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).

Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na+) plays a major role in maintaining physiologic equilibrium.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Intravenous solutions containing sodium chloride are indicated for parenteral replenishment of fluid and sodium chloride as required by the clinical condition of the patient.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

None known.

WARNINGS

WARNINGS SECTION

Sodium Chloride Injection, USP should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.

The intravenous administration of Sodium Chloride Injection, USP can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.

The risk of dilutive states is inversely proportional to the electrolyte concentration of the injections. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injections.

In patients with diminished renal function, administration of Sodium Chloride Injection, USP may result in sodium retention.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.

Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.

Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.

Laboratory Tests

LABORATORY TESTS SECTION

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility.

Pregnancy:

PREGNANCY SECTION

Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP. It is also not known whether Sodium Chloride Injection, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Chloride Injection, USP should be given to a pregnant woman only if clearly needed.

Labor and Delivery

LABOR & DELIVERY SECTION

Studies have not been conducted to evaluate the effects of Sodium Chloride Injection, USP on labor and delivery. Caution should be exercised when administering this drug during labor and delivery.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Sodium Chloride Injection, USP is administered to a nursing mother.

Pediatric Use

PEDIATRIC USE SECTION

The use of Sodium Chloride Injection, USP in pediatric patients is based on clinical practice.

Plasma electrolyte concentrations should be closely monitored in the pediatric population as this population may have impaired ability to regulate fluids and electrolytes.

Geriatric Use

GERIATRIC USE SECTION

Clinical studies of Sodium Chloride Injection, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Do not administer unless solution is clear and container is undamaged. Discard unused portion.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

OVERDOSAGE

OVERDOSAGE SECTION

In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures (see WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS).

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The dose is dependent upon the age, weight and clinical condition of the patient.

Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit (see PRECAUTIONS).

INSTRUCTIONS FOR USE

INSTRUCTIONS FOR USE SECTION

Check flexible container solution composition, lot number, and expiry date.

Do not remove solution container from its overwrap until immediately before use.

Use sterile equipment and aseptic technique.

To Open

  1. Turn solution container over so that the text is face down. Using the pre-cut corner tabs, peel open the overwrap and remove solution container.
  2. Check the solution container for leaks by squeezing firmly. If leaks are found, or if the seal is not intact, discard the solution.
  3. Do not use if the solution is cloudy or a precipitate is present.

To Add Medication

  1. Identify WHITE Additive Port with arrow pointing toward container.
  2. Immediately before injecting additives, break off WHITE Additive Port Cap with the arrow pointing toward container.
  3. Hold base of WHITE Additive Port horizontally.
  4. Insert needle horizontally through the center of WHITE Additive Port's septum and inject additives.
  5. Mix container contents thoroughly.

Preparation for Administration

  1. Immediately before inserting the infusion set, break off BLUE Infusion Port Cap with the arrow pointing away from container.
  2. Use a non-vented infusion set or close the air-inlet on a vented set.
  3. Close the roller clamp of the infusion set.
  4. Hold the base of BLUE Infusion Port.
  5. Insert spike through BLUE Infusion Port by rotating wrist slightly until the spike is inserted.

    NOTE: See full directions accompanying administration set.

WARNING: Do not use flexible container in series connections.

HOW SUPPLIED

HOW SUPPLIED SECTION

0.9% Sodium Chloride Injection, USP is supplied in single-dose flexible plastic containers as follows:

Product Code Unit of Sale Strength Each
6B1275 NDC 63323-632-75
Package of 20
free flex ® bags
0.9% (9 mg/mL) NDC 63323-632-20
500 mL free flex ® bag
6B1440 NDC 63323-632-40
Package of 10
free flex ® bags
0.9% (9 mg/mL) NDC 63323-632-10
1000 mL free flex ® bag

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing.

The container closure is not made with natural rubber latex. Non-PVC, Non-DEHP, Sterile.

Manufactured for:

Fresenius Kabi LogoFresenius Kabi Logo

Lake Zurich, IL 60047
www.fresenius-kabi.com/us
Made in Germany

451536A
Revised: October 2021

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL


PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - Sodium Chloride 500 mL Bag Label


fflogofflogo                        500 mL

0.9% Sodium Chloride Injection, USP

For intravenous use.
Rx only


bagbag

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1807639sodium chloride 0.9 % in 1000 ML InjectionPSN3
1807634sodium chloride 0.9 % in 500 ML InjectionPSN3
18076391000 ML sodium chloride 9 MG/ML InjectionSCD3
1807634500 ML sodium chloride 9 MG/ML InjectionSCD3
18076391000 ML NaCl 9 MG/ML InjectionSY3
1807634500 ML NaCl 9 MG/ML InjectionSY3
1807639sodium chloride 0.9 % per 1000 ML InjectionSY3
1807634sodium chloride 0.9 % per 500 ML InjectionSY3

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
95250459-30e4-45c1-b08a-993044f49109Product name220250805
30b0ac6e-02aa-0e5c-0d8b-cffdf3a282b2Product name520250304
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
a21a21e5-f36d-4c1f-8918-def921b8f7e3Product name320250124
bed0530e-f939-4541-956b-6928a2f6404fProduct name120241008
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name620240814
fb7ab793-2c12-4079-b100-a64f73bef25aProduct name420240712
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
b0cbf770-6cc3-4aa4-9158-755110c2b9f7Product name220230717
dc7c5daa-021f-40dd-b00d-63982cb2067aProduct name120230426
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
9badc7be-250a-44ab-aa36-926af3f02679Product name120210527
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name520200925
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name220171212
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
26acd337-b838-40ac-bcbc-05c3b81c8712Product name120170323
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name220160823
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
597b1cfd-7b31-5048-62be-ca5cd740da2fProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
63323-632-10Sodium Chloride1000 mL in 1 BAGINJECTION, SOLUTION10003
63323-632-20Sodium Chloride500 mL in 1 BAGINJECTION, SOLUTION5003
63323-632-40Sodium Chloride10 in 1 CASEINJECTION, SOLUTION103
63323-632-75Sodium Chloride20 in 1 CASEINJECTION, SOLUTION203

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
63323-632SODIUM CHLORIDE INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ]3Current NDC, Legacy NDC, 4 package rows20220211_4829ee40-c2d7-4e17-a606-75e8a8628413.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
63323-63263323-632-20, 63323-632-75, 63323-632-10, 63323-632-40

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
SODIUM CHLORIDE451W47IQ8XACTIB

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERSODIUM CHLORIDE900MG/100MLINJECTABLE / INJECTIONAP2017-09-19

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A207310-001AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-1984e616aacf4f…
2026-08-18 06:07:402026-07A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-1931067a03dcf5…
2025-08-23 18:47 UTC2025-08A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-196a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-1903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-192680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-195bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-1979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-191e350fbaab3a…
2024-05-31 18:47 UTC2024-05A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-198072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-195c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-195d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-194b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-1974a2ff9319b5…
2022-03-09 01:35 UTC2022-03A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-1987673890dc5c…
2021-03-12 10:30 UTC2021-03A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-195aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-198869cabd3fbd…
2020-11-12 02:37 UTC2020-11A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19c0c555d07b60…
2019-12-14 00:12 UTC2019-12A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-193f01610625f2…
2019-09-15 20:21 UTC2019-09A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19b00525d2431f…
2019-07-19 19:46 UTC2019-07A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-196a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-191c564ffb4f44…
2023-12-20 04:57 UTC2023-12A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-199b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-193f0d92c62455…
2023-05-13 08:27 UTC2023-05A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19053a50430f4f…
2023-01-26 05:58 UTC2023-01A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-193bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-193a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A207310-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER900MG/100MLINJECTABLE / INJECTIONAP2017-09-19f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A207310-001AP184e616aacf4f…
2026-08-18 06:07:402026-07A207310-001AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A207310-001AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A207310-001AP131067a03dcf5…
2025-08-23 18:47 UTC2025-08A207310-001AP16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A207310-001AP1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A207310-001AP1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A207310-001AP103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A207310-001AP12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A207310-001AP15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A207310-001AP1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A207310-001AP1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A207310-001AP179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A207310-001AP1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A207310-001AP11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A207310-001AP18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A207310-001AP15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A207310-001AP15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A207310-001AP14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A207310-001AP174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A207310-001AP1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A207310-001AP1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A207310-001AP187673890dc5c…
2021-03-12 10:30 UTC2021-03A207310-001AP15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A207310-001AP18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A207310-001AP1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A207310-001AP13f01610625f2…
2019-09-15 20:21 UTC2019-09A207310-001AP1b00525d2431f…
2019-07-19 19:46 UTC2019-07A207310-001AP1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A207310-001AP16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A207310-001AP11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A207310-001AP1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A207310-001AP1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A207310-001AP19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A207310-001AP1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A207310-001AP13f0d92c62455…
2023-05-13 08:27 UTC2023-05A207310-001AP1053a50430f4f…
2023-01-26 05:58 UTC2023-01A207310-001AP13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A207310-001AP13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A207310-001AP1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Sodium ChlorideSODIUM CHLORIDEFresenius Kabi USA, LLC4829ee40-c2d7-4e17-a606-75e8a86284132021-12-21Warnings, Adverse reactionsExact identifier
ndc (package): 63323-632-20
ndc (package): 63323-632-40
ndc (package): 63323-632-75
ndc (package): 63323-632-10
ndc (product): 63323-632
ndc11 (package): 63323063240
ndc11 (package): 63323063210
ndc11 (package): 63323063220
ndc11 (package): 63323063275
spl id: b1de166c-c503-4d64-980e-f7177970f9ed
spl set id: 4829ee40-c2d7-4e17-a606-75e8a8628413

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.